Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue.
Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue.
复制标题
DOI：
10.1186/1746-1596-9-30
复制
发表时间：
2014-02-06
影响因子：
2.6
通讯作者：
Morimoto C
中科院分区：
文献类型：
--
作者：
Hatano R;Yamada T;Matsuoka S;Iwata S;Yamazaki H;Komiya E;Okamoto T;Dang NH;Ohnuma K;Morimoto C
CD26是一种细胞外区具有二肽基肽酶IV （DPPIV）活性的T细胞共刺激分子，是一种与腺苷脱氨酶、caveolin-1、CXCR4、胶原蛋白、纤维连接蛋白等多种蛋白相关的多功能分子，在炎症反应和肿瘤生物学调控中发挥重要作用。我们专注于将CD26作为各种肿瘤和免疫疾病的新治疗靶点，并开发了一种人源化抗CD26单克隆抗体（mAb） YS110，目前正在针对表达CD26的肿瘤（包括恶性间皮瘤）患者的I期临床试验中进行评估。由于检测肿瘤CD26表达是确定YS110治疗的潜在资格的必要条件，因此开发能够清晰可靠地检测福尔马林固定石蜡包埋组织中变性CD26分子的抗人CD26单抗至关重要。为了开发能够与变性CD26结合的新型抗CD26单抗，我们用尿素缓冲液中变性的CD26蛋白免疫小鼠。脾细胞和骨髓瘤细胞融合后，通过流式细胞术、酶联免疫吸附试验和免疫组织化学筛选单克隆抗体与人CD26的特异性反应性。我们还检测了新型抗cd26单抗与人源抗cd26单抗YS110的结合竞争力。我们已经成功开发了新的抗人CD26单克隆抗体，适用于福尔马林固定组织切片中CD26的免疫组织化学染色，具有可靠的清晰度和强度。重要的是，其中一些单抗与人源抗cd26单抗没有交叉反应性。这些新型单克隆抗体可能作为辅助诊断试剂在临床环境中分析CD26表达，同时推进未来CD26相关研究。本文的虚拟幻灯片可以在这里找到：http://www.diagnosticpathology.diagnomx.eu/vs/5987140221097729
A T cell costimulatory molecule with dipeptidyl peptidase IV (DPPIV) activity in its extracellular region, CD26 is a multifunctional molecule associated with various proteins such as adenosine deaminase, caveolin-1, CXCR4, collagen, and fibronectin, while playing an important role in the regulation of inflammatory responses and tumor biology. We have focused on CD26 as a novel therapeutic target for various tumors and immune disorders, and have developed a humanized anti-CD26 monoclonal antibody (mAb), YS110, which is currently being evaluated in a phase I clinical trial for patients with CD26-expressing tumors, including malignant mesothelioma. Since detection of tumor CD26 expression is required for determining potential eligibility for YS110 therapy, the development of anti-human CD26 mAb that can clearly and reliably detect the denatured CD26 molecule in the formalin-fixed paraffin-embedded tissues is critical. To develop novel anti-CD26 mAbs capable of binding to the denatured CD26, we immunized mice with CD26 protein denatured in urea buffer. After the fusion of splenocytes and myeloma cells, the mAbs were screened for specific reactivity with human CD26 by flow cytometry, enzyme-linked immunosorbent assay, and immunohistochemistry. The binding competitiveness of novel anti-CD26 mAbs with the humanized anti-CD26 mAb YS110 was also examined. We have succeeded in developing novel anti-human CD26 mAbs suitable for immunohistochemical staining of CD26 in formalin-fixed tissue sections with reliable clarity and intensity. Importantly, some of these mAbs exhibit no cross-reactivity with the humanized anti-CD26 mAb. These novel mAbs are potentially useful as companion diagnostic agents to analyze CD26 expression in the clinical setting while advancing future CD26-related research. The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5987140221097729
登录
查看更多内容
DOI：
10.1006/bbrc.1999.1617
发表时间：
1999-11-02
影响因子：
3.1
作者：
Tanaka, J;Miwa, Y;Inoue, H
通讯作者：
Inoue, H
影响因子：
11.5
作者：
Inamoto, Teruo;Yamochi, Tadanori;Morimoto, Chikao
通讯作者：
Morimoto, Chikao
DOI：
10.1073/pnas.97.15.8439
发表时间：
2000-07-18
影响因子：
11.1
作者：
Ikushima, H;Munakata, Y;Morimoto, C
通讯作者：
Morimoto, C
DOI：
10.1073/pnas.91.8.3082
发表时间：
1994-04-12
影响因子：
11.1
作者：
TANAKA, T;DUKECOHAN, JS;MORIMOTO, C
通讯作者：
MORIMOTO, C
影响因子：
2.6
作者：
Hua X;Yu L;Huang X;Liao Z;Xian Q
通讯作者：
Xian Q